NCT02567435 2026-03-17
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
Children's Oncology Group
Eisai Inc.
Children's Oncology Group
National Cancer Institute (NCI)